candesartan cilexetil has been researched along with Breast Cancer in 4 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this 2×2 factorial, randomized, placebo-controlled, double-blind, single-center trial, patients with early breast cancer were assigned to concomitant treatment with candesartan cilexetil, metoprolol succinate, or matching placebos." | 9.41 | Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. ( Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Mecinaj, A; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K, 2021) |
| "In a 2 × 2 factorial, randomized, placebo-controlled, double-blind trial, we assigned 130 adult women with early breast cancer and no serious co-morbidity to the angiotensin receptor blocker candesartan cilexetil, the β-blocker metoprolol succinate, or matching placebos in parallel with adjuvant anticancer therapy." | 9.22 | Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. ( Bratland, Å; Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2016) |
| "In this 2×2 factorial, randomized, placebo-controlled, double-blind, single-center trial, patients with early breast cancer were assigned to concomitant treatment with candesartan cilexetil, metoprolol succinate, or matching placebos." | 5.41 | Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. ( Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Mecinaj, A; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K, 2021) |
| " The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines." | 5.24 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. ( Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K, 2017) |
| "In a 2 × 2 factorial, randomized, placebo-controlled, double-blind trial, we assigned 130 adult women with early breast cancer and no serious co-morbidity to the angiotensin receptor blocker candesartan cilexetil, the β-blocker metoprolol succinate, or matching placebos in parallel with adjuvant anticancer therapy." | 5.22 | Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. ( Bratland, Å; Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2016) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Heck, SL | 3 |
| Mecinaj, A | 1 |
| Ree, AH | 3 |
| Hoffmann, P | 3 |
| Schulz-Menger, J | 2 |
| Fagerland, MW | 2 |
| Gravdehaug, B | 3 |
| Røsjø, H | 3 |
| Steine, K | 3 |
| Geisler, J | 3 |
| Gulati, G | 3 |
| Omland, T | 3 |
| Hagve, TA | 2 |
| Norseth, J | 1 |
| von Knobelsdorff-Brenkenhoff, F | 1 |
| Bratland, Å | 1 |
| Storås, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.[NCT03392740] | Phase 4 | 200 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Breast Cancer
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
3 trials available for candesartan cilexetil and Breast Cancer